Plasma proteins as modifiable drivers of age-related disease
PrimaryAlkahest's central premise is that changes in the plasma proteome influence human biology and can therefore reveal therapeutic targets for age-related disease. Its discovery platform uses proteomics, multiomics, artificial intelligence, and clinical data to identify plasma factors that might causally influence disease processes. The testable prediction is that modifying a causally active plasma factor will alter the associated disease process. Predicting disease from protein abundance alone would establish biomarker utility, but would not establish this therapeutic mechanism.
Popperian evaluation
Plasma proteins plausibly contribute to disease processes, and the supplied intervention study establishes that a plasma fraction can alter human immune responses. The larger claim that specific circulating factors are therapeutically modifiable drivers of age-related disease remains incompletely supported.
Supporting evidence: The randomized trial in 38 older surgical patients found that a young-donor plasma protein fraction altered inflammatory pathways and cellular immune responses.; The observed changes included JAK-STAT, NF-kappa B, and MAPK signaling, providing mechanistic evidence of biological activity.
Counter evidence: The plasma-fraction trial did not identify the individual proteins responsible or establish efficacy against an age-related disease.; Protein abundance can change as a consequence of disease, so disease-associated proteins need not be causal contributors.
The theory accommodates the reported observations, but the supplied evidence provides limited discrimination between causal disease drivers and proteins that track tissue damage, inflammation, or other disease processes. The intervention result supports a narrower explanation: plasma components can modulate responses to surgical injury.
Supporting evidence: Randomized administration of a plasma fraction changed immune responses, supporting a causal effect of the administered mixture.; The 14-protein extracellular matrix clock, Parkinson's prediction study, and mortality associations establish relationships between plasma composition and health outcomes.
Counter evidence: The observational findings remain compatible with reverse causation and shared upstream causes.; The Parkinson's study's maximum cross-validated AUC of 0.76 measures predictive discrimination; it supplies no intervention test of the proposed therapeutic mechanism.; The supplied evidence does not show that changing a specified protein improves its associated disease process.
Individual target hypotheses are testable if they specify the protein, direction of modification, disease endpoint, expected effect, and timeframe before intervention. The broad prediction is weaker because describing a factor as causally active already assumes that changing it has an effect, and failed candidates leave the existence of other causal factors open.
Supporting evidence: A controlled intervention with verified target engagement can test whether changing a nominated protein alters a prespecified disease endpoint.; A sufficiently precise null result could contradict a candidate-specific prediction under the tested conditions.
Counter evidence: The theory names no specific factor, required effect size, disease endpoint, or response timeframe.; Failure of one candidate cannot refute the broad claim that some plasma factors contribute causally to age-related disease.
Reasoning tree
Public endorsements
Lehallier is named as an inventor on a patent for organ-aging biomarkers derived from the plasma proteome. That supports his public involvement with plasma-protein measurement and aging biology. The supplied evidence does not show him claiming that modifying a plasma factor changes an age-related disease process.
Evidence publication IDs: 5b932296-1191-4abb-a9c8-4218b72ec06b
The available record concerns rapid pediatric genome sequencing and contains no statement from Chunmiao Feng about Alkahest, plasma proteins, or modifying plasma factors to treat age-related disease.
Kosti coauthored a 2024 study linking proteomic profiles to depression, inflammation, and cardiometabolic risk factors, and describing proteins as potential biomarkers and intervention pathways. It does not test whether changing a plasma factor alters disease, so it does not publicly endorse Alkahest's causal therapeutic premise.
Evidence publication IDs: d6915306-f9a1-4f69-8681-dcc0eeecdb21
The supplied record concerns rapid genome sequencing for pediatric care and contains no statement from Nathan Watson-Haigh about Alkahest, plasma proteins, or their causal role in age-related disease.
The dossier identifies Scott Lohr as Alkahest's Senior Vice President of Informatics, but contains no public statement from him about plasma proteins as causal drivers of age-related disease. The cited publication and company material are not attributed to Lohr.